Raymond James & Associates
ONCE

Raymond James & Associates’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Raymond James & Associates’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,723
Closed -$312K – 3772
2018
Q3 		$312K Sell
5,723
-398
-7% -$27.2K ﹤0.01% 3002
2018
Q2 		$507K Buy
+6,121
New +$472K ﹤0.01% 2679
2017
Q4 		– Sell
-3,820
Closed -$341K – 3581
2017
Q3 		$341K Buy
+3,820
New +$290K ﹤0.01% 2702

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Raymond James & Associates's ONCE Position: Q4 2018 in Review

Raymond James & Associates sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2018, closing a stake of 5,723 shares — an estimated $312K sold.

Raymond James & Associates first reported a position in ONCE in Q3 2017 and held it in 3 quarters. The position peaked at $507K in Q2 2018. 157 funds tracked by Wall St. Rank hold ONCE as of Q4 2018.

  • Raymond James & Associates reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Raymond James & Associates sold 5,723 Spark Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $312K.
  • Raymond James & Associates first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2017 and held it in 3 quarters.
  • Raymond James & Associates's Spark Therapeutics, Inc. Common Stock position peaked at $507K in Q2 2018.
  • 157 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Raymond James & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.